The  	The  	 DT	O
problem  	problem  	 NN	O
Three  	Three  	 CD	O
published  	published  	 NNS	O
[  	[  	 -LRB-	O
1  	1  	 CD	O
2  	2  	 CD	O
3  	3  	 CD	O
]  	]  	 -RRB-	O
and  	and  	 CC	O
one  	one  	 CD	O
recently  	recently  	 RB	O
presented  	presented  	 VBN	O
[  	[  	 -LRB-	O
4  	4  	 LS	O
]  	]  	 -RRB-	O
randomized  	randomized  	 JJ	B-NP
placebo-controlled  	placebo-controlled  	 JJ	I-NP
clinical  	clinical  	 JJ	I-NP
trial  	trial  	 NN	I-NP
have  	have  	 VBP	O
unequivocally  	unequivocally  	 RB	O
demonstrated  	demonstrated  	 VBN	O
that  	that  	 IN	O
3-Hydroxy-3-methylgluatryl  	3-Hydroxy-3-methylgluatryl  	 NNP	O
coenzyme  	coenzyme  	 VBD	O
A  	A  	 DT	O
( 	( 	 -LRB-	O
HMG  	HMG  	 NNP	O
CoA 	CoA 	 NNP	O
)  	)  	 -RRB-	O
reductase  	reductase  	 FW	B-NP
inhibitors  	inhibitors  	 FW	I-NP
( 	( 	 -LRB-	O
statins 	statins 	 LS	B-NP
)  	)  	 -RRB-	O
reduce  	reduce  	 VB	O
the  	the  	 DT	O
morbidity  	morbidity  	 NN	O
and  	and  	 CC	O
mortality  	mortality  	 NN	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
coronary  	coronary  	 JJ	B-NP
disease 	disease 	 NN	I-NP
.  	.  	 .	O
These  	These  	 DT	O
trials  	trials  	 NNS	O
found  	found  	 VBD	O
that  	that  	 IN	O
when  	when  	 WRB	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
placebo 	placebo 	 NN	O
,  	,  	 ,	O
statins  	statins  	 VBD	O
significantly  	significantly  	 RB	O
reduced  	reduced  	 VBN	O
the  	the  	 DT	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
death 	death 	 NN	O
,  	,  	 ,	O
myocardial  	myocardial  	 JJ	B-NP
infarction 	infarction 	 NN	I-NP
,  	,  	 ,	O
unstable  	unstable  	 JJ	O
angina 	angina 	 NN	O
,  	,  	 ,	O
percutaneous  	percutaneous  	 NN	B-NP
and  	and  	 CC	O
surgical  	surgical  	 JJ	B-NP
coronary  	coronary  	 JJ	I-NP
revascularization 	revascularization 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
stroke  	stroke  	 NN	O
in  	in  	 IN	O
persons  	persons  	 NNS	O
with  	with  	 IN	O
stable  	stable  	 JJ	O
coronary  	coronary  	 JJ	B-NP
disease 	disease 	 NN	I-NP
.  	.  	 .	O
Because  	Because  	 IN	O
patients  	patients  	 NNS	O
who  	who  	 WP	O
had  	had  	 VBD	O
experienced  	experienced  	 VBN	O
an  	an  	 DT	O
acute  	acute  	 JJ	B-NP
coronary  	coronary  	 JJ	I-NP
syndrome  	syndrome  	 NN	I-NP
within  	within  	 IN	O
three  	three  	 CD	O
to  	to  	 TO	O
six  	six  	 CD	O
months  	months  	 NNS	O
of  	of  	 IN	O
enrollment  	enrollment  	 NN	O
were  	were  	 VBD	O
excluded 	excluded 	 VBN	O
,  	,  	 ,	O
these  	these  	 DT	O
trials  	trials  	 NNS	O
did  	did  	 VBD	O
not  	not  	 RB	O
assess  	assess  	 VB	O
the  	the  	 DT	O
effect  	effect  	 NN	O
of  	of  	 IN	O
lipid-lowering  	lipid-lowering  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
on  	on  	 IN	O
adverse  	adverse  	 JJ	O
cardiovascular  	cardiovascular  	 JJ	B-NP
events  	events  	 NNS	I-NP
in  	in  	 IN	O
those  	those  	 DT	O
with  	with  	 IN	O
recently  	recently  	 RB	O
unstable  	unstable  	 JJ	O
coronary  	coronary  	 JJ	B-NP
disease 	disease 	 NN	I-NP
.  	.  	 .	O
Whether  	Whether  	 IN	O
lipid-lowering  	lipid-lowering  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
would  	would  	 MD	O
provide  	provide  	 VB	O
incremental  	incremental  	 JJ	B-NP
benefit  	benefit  	 NN	I-NP
if  	if  	 IN	O
initiated  	initiated  	 VBN	O
immediately  	immediately  	 RB	O
following  	following  	 VBG	O
an  	an  	 DT	O
acute  	acute  	 JJ	B-NP
coronary  	coronary  	 JJ	I-NP
syndrome  	syndrome  	 NN	I-NP
is  	is  	 VBZ	O
an  	an  	 DT	O
important  	important  	 JJ	O
issue  	issue  	 NN	O
as  	as  	 IN	O
the  	the  	 DT	O
risk  	risk  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
recurrent  	recurrent  	 JJ	O
adverse  	adverse  	 JJ	O
cardiac  	cardiac  	 JJ	B-NP
events  	events  	 NNS	I-NP
is  	is  	 VBZ	O
much  	much  	 RB	O
greater  	greater  	 JJR	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
unstable  	unstable  	 JJ	O
coronary  	coronary  	 JJ	B-NP
disease  	disease  	 NN	I-NP
than  	than  	 IN	O
in  	in  	 IN	O
the  	the  	 DT	O
stable  	stable  	 JJ	O
setting 	setting 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
Myocardial  	Myocardial  	 NNP	B-NP
Ischemia  	Ischemia  	 NNP	I-NP
Reduction  	Reduction  	 NNP	I-NP
with  	with  	 IN	O
Aggressive  	Aggressive  	 NNP	B-NP
Cholesterol  	Cholesterol  	 NNP	I-NP
Lowering  	Lowering  	 NNP	O
( 	( 	 -LRB-	O
MIRACL 	MIRACL 	 NNP	O
)  	)  	 -RRB-	O
trial  	trial  	 NN	O
set  	set  	 VBN	O
out  	out  	 RP	O
to  	to  	 TO	O
answer  	answer  	 VB	O
this  	this  	 DT	O
question 	question 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
answer 	answer 	 NN	O
?  	?  	 .	O
MIRACL  	MIRACL  	 NNP	B-NP
enrolled  	enrolled  	 VBD	O
3,086  	3,086  	 CD	O
patients  	patients  	 NNS	O
within  	within  	 IN	O
24-96  	24-96  	 CD	O
hours  	hours  	 NNS	O
( 	( 	 -LRB-	O
mean  	mean  	 VB	B-NP
63  	63  	 CD	O
hours 	hours 	 NNS	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
admission  	admission  	 NN	B-NP
for  	for  	 IN	O
unstable  	unstable  	 JJ	O
angina  	angina  	 NN	O
or  	or  	 CC	O
a  	a  	 DT	O
non-Q-wave  	non-Q-wave  	 JJ	B-NP
myocardial  	myocardial  	 JJ	I-NP
infarction  	infarction  	 NN	I-NP
and  	and  	 CC	O
randomized  	randomized  	 VBD	O
them  	them  	 PRP	O
to  	to  	 TO	O
16  	16  	 CD	O
weeks  	weeks  	 NNS	O
of  	of  	 IN	O
atorvastatin  	atorvastatin  	 CD	B-NP
80  	80  	 CD	O
mg  	mg  	 NNS	B-NP
or  	or  	 CC	O
placebo  	placebo  	 VBP	O
once  	once  	 RB	O
daily  	daily  	 JJ	O
[  	[  	 -LRB-	O
5  	5  	 LS	O
]  	]  	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
major  	major  	 JJ	O
exclusion  	exclusion  	 NN	B-NP
criteria  	criteria  	 NNS	I-NP
were 	were 	 VBD	O
:  	:  	 :	O
total  	total  	 JJ	B-NP
cholesterol  	cholesterol  	 NN	I-NP
level  	level  	 NN	I-NP
greater  	greater  	 JJR	O
than  	than  	 IN	O
270  	270  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
dL 	dL 	 NN	I-NP
;  	;  	 :	O
Q-wave  	Q-wave  	 JJ	B-NP
myocardial  	myocardial  	 JJ	I-NP
infarction  	infarction  	 NN	I-NP
on  	on  	 IN	O
admission  	admission  	 NN	B-NP
or  	or  	 CC	O
during  	during  	 IN	O
the  	the  	 DT	O
previous  	previous  	 JJ	O
month 	month 	 NN	O
;  	;  	 :	O
and 	and 	 CC	O
,  	,  	 ,	O
coronary  	coronary  	 JJ	B-NP
revascularization  	revascularization  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
months  	months  	 NNS	O
before  	before  	 IN	O
admission 	admission 	 NN	B-NP
,  	,  	 ,	O
during  	during  	 IN	O
the  	the  	 DT	O
index  	index  	 NN	B-NP
hospitalization  	hospitalization  	 NN	I-NP
or  	or  	 CC	O
anticipated  	anticipated  	 VBN	O
following  	following  	 VBG	O
hospital  	hospital  	 NN	B-NP
discharge 	discharge 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
primary  	primary  	 JJ	B-NP
efficacy  	efficacy  	 JJ	I-NP
endpoint  	endpoint  	 NN	I-NP
was  	was  	 VBD	O
a  	a  	 DT	O
composite  	composite  	 JJ	O
of  	of  	 IN	O
death 	death 	 NN	O
,  	,  	 ,	O
non-fatal  	non-fatal  	 JJ	B-NP
myocardial  	myocardial  	 JJ	I-NP
infarction 	infarction 	 NN	I-NP
,  	,  	 ,	O
resuscitated  	resuscitated  	 JJ	O
sudden  	sudden  	 JJ	O
cardiac  	cardiac  	 JJ	B-NP
death  	death  	 NN	I-NP
or  	or  	 CC	O
emergent  	emergent  	 JJ	O
rehospitalization  	rehospitalization  	 NN	B-NP
for  	for  	 IN	O
worsening  	worsening  	 VBG	O
symptomatic  	symptomatic  	 JJ	B-NP
myocardial  	myocardial  	 JJ	I-NP
ischemia 	ischemia 	 NN	I-NP
.  	.  	 .	O
Secondary  	Secondary  	 JJ	B-NP
endpoints  	endpoints  	 NN	I-NP
included  	included  	 VBD	I-NP
stroke 	stroke 	 NN	I-NP
,  	,  	 ,	O
worsening  	worsening  	 VBG	B-NP
heart  	heart  	 NN	I-NP
failure 	failure 	 NN	I-NP
,  	,  	 ,	O
need  	need  	 VBP	O
for  	for  	 IN	O
coronary  	coronary  	 JJ	B-NP
revascularization  	revascularization  	 NN	I-NP
and  	and  	 CC	O
change  	change  	 NN	O
in  	in  	 IN	O
lipid  	lipid  	 JJ	B-NP
levels  	levels  	 NNS	I-NP
throughout  	throughout  	 IN	O
the  	the  	 DT	O
study 	study 	 NN	O
.  	.  	 .	O
On  	On  	 IN	O
average 	average 	 NN	O
,  	,  	 ,	O
patients  	patients  	 NNS	O
were  	were  	 VBD	O
65  	65  	 CD	O
years  	years  	 NNS	O
of  	of  	 IN	O
age 	age 	 NN	O
,  	,  	 ,	O
approximately  	approximately  	 RB	O
65 	65 	 CD	O
%  	%  	 NN	O
were  	were  	 VBD	O
men 	men 	 NNS	O
,  	,  	 ,	O
86 	86 	 CD	O
%  	%  	 NN	O
Caucasian  	Caucasian  	 NNP	B-NP
and  	and  	 CC	O
the  	the  	 DT	O
mean  	mean  	 JJ	B-NP
baseline  	baseline  	 NN	I-NP
low  	low  	 JJ	O
density  	density  	 NN	B-NP
lipoprotein  	lipoprotein  	 NNS	I-NP
( 	( 	 -LRB-	O
LDL 	LDL 	 NNP	B-NP
)  	)  	 -RRB-	O
cholesterol  	cholesterol  	 NN	B-NP
level  	level  	 NN	I-NP
was  	was  	 VBD	O
124  	124  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
dL 	dL 	 NN	I-NP
.  	.  	 .	O
Atorvastatin  	Atorvastatin  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
was  	was  	 VBD	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
2.6 	2.6 	 CD	O
%  	%  	 NN	O
absolute  	absolute  	 JJ	B-NP
reduction  	reduction  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
risk  	risk  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
primary  	primary  	 JJ	B-NP
endpoint  	endpoint  	 NNS	I-NP
( 	( 	 -LRB-	O
14.8 	14.8 	 CD	O
%  	%  	 NN	O
vs.  	vs.  	 IN	O
17.4 	17.4 	 CD	O
% 	% 	 NN	O
;  	;  	 :	O
RR  	RR  	 NNP	B-NP
relative  	relative  	 JJ	I-NP
risk  	risk  	 NN	I-NP
[ 	[ 	 -LRB-	O
RR 	RR 	 NNP	B-NP
]  	]  	 -RRB-	O
0.84 	0.84 	 CD	O
,  	,  	 ,	O
95 	95 	 CD	O
%  	%  	 NN	O
confidence  	confidence  	 NN	B-NP
interval  	interval  	 NNS	I-NP
[ 	[ 	 -LRB-	O
CI 	CI 	 NNP	O
]  	]  	 -RRB-	O
0.70-1.00 	0.70-1.00 	 NNP	O
,  	,  	 ,	O
p  	p  	 VBG	O
=  	=  	 SYM	O
0.048 	0.048 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
This  	This  	 DT	O
reduction  	reduction  	 NN	O
was  	was  	 VBD	O
primarily  	primarily  	 RB	O
driven  	driven  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
2.2 	2.2 	 CD	O
%  	%  	 NN	O
absolute  	absolute  	 JJ	B-NP
reduction  	reduction  	 NN	I-NP
in  	in  	 IN	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
emergent  	emergent  	 JJ	O
rehospitalization  	rehospitalization  	 NN	B-NP
for  	for  	 IN	I-NP
symptomatic  	symptomatic  	 FW	I-NP
myocardial  	myocardial  	 FW	I-NP
ischemia  	ischemia  	 FW	I-NP
( 	( 	 -LRB-	O
6.2 	6.2 	 CD	O
%  	%  	 NN	O
vs.  	vs.  	 IN	O
8.4 	8.4 	 CD	O
% 	% 	 NN	O
;  	;  	 :	O
RR  	RR  	 NNP	B-NP
0.74 	0.74 	 NNP	O
,  	,  	 ,	O
95 	95 	 CD	O
%  	%  	 NN	O
CI  	CI  	 NNP	O
0.57-0.95 	0.57-0.95 	 NNP	O
,  	,  	 ,	O
p  	p  	 VBG	O
=  	=  	 SYM	O
0.02 	0.02 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
risk  	risk  	 NN	O
of  	of  	 IN	O
death 	death 	 NN	O
,  	,  	 ,	O
nonfatal  	nonfatal  	 FW	B-NP
myocardial  	myocardial  	 FW	I-NP
infarction  	infarction  	 FW	I-NP
and  	and  	 CC	O
resuscitated  	resuscitated  	 JJ	O
sudden  	sudden  	 JJ	O
cardiac  	cardiac  	 JJ	B-NP
death  	death  	 NN	I-NP
were  	were  	 VBD	O
each  	each  	 DT	O
no  	no  	 DT	O
different  	different  	 JJ	O
between  	between  	 IN	O
the  	the  	 DT	O
two  	two  	 CD	O
groups 	groups 	 NNS	O
.  	.  	 .	O
While  	While  	 IN	O
there  	there  	 EX	O
were  	were  	 VBD	O
no  	no  	 DT	O
significant  	significant  	 JJ	O
differences  	differences  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
worsening  	worsening  	 VBG	B-NP
heart  	heart  	 NN	I-NP
failure  	failure  	 NN	I-NP
or  	or  	 CC	O
need  	need  	 NN	O
for  	for  	 IN	O
coronary  	coronary  	 JJ	B-NP
revascularization 	revascularization 	 NN	I-NP
,  	,  	 ,	O
atorvastatin  	atorvastatin  	 NN	B-NP
did  	did  	 VBD	O
reduce  	reduce  	 VB	O
the  	the  	 DT	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
fatal  	fatal  	 JJ	O
or  	or  	 CC	O
non-fatal  	non-fatal  	 JJ	B-NP
stroke  	stroke  	 NN	I-NP
by  	by  	 IN	O
0.8 	0.8 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
0.8 	0.8 	 CD	O
%  	%  	 NN	O
vs.  	vs.  	 IN	O
1.6 	1.6 	 CD	O
% 	% 	 NN	O
;  	;  	 :	O
RR  	RR  	 NNP	B-NP
0.50 	0.50 	 NNP	O
,  	,  	 ,	O
95 	95 	 CD	O
%  	%  	 NN	O
CI  	CI  	 NNP	O
0.26-0.99 	0.26-0.99 	 NNP	O
,  	,  	 ,	O
p  	p  	 VBG	O
=  	=  	 SYM	O
0.045 	0.045 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Atorvastatin  	Atorvastatin  	 NNP	B-NP
also  	also  	 RB	O
significantly  	significantly  	 RB	O
reduced  	reduced  	 VBN	O
total  	total  	 JJ	O
and  	and  	 CC	O
LDL  	LDL  	 NNP	B-NP
cholesterol  	cholesterol  	 NN	I-NP
and  	and  	 CC	O
triglyceride  	triglyceride  	 JJ	B-NP
levels  	levels  	 NNS	I-NP
but  	but  	 CC	O
did  	did  	 VBD	O
not  	not  	 RB	O
significantly  	significantly  	 RB	O
change  	change  	 VB	O
high  	high  	 JJ	B-NP
density  	density  	 NN	I-NP
lipoprotein  	lipoprotein  	 NNS	I-NP
( 	( 	 -LRB-	O
HDL 	HDL 	 NNP	B-NP
)  	)  	 -RRB-	O
cholesterol  	cholesterol  	 NN	B-NP
by  	by  	 IN	O
16  	16  	 CD	O
weeks 	weeks 	 NNS	O
.  	.  	 .	O
By  	By  	 IN	O
16  	16  	 CD	O
weeks 	weeks 	 NNS	O
,  	,  	 ,	O
the  	the  	 DT	O
adjusted  	adjusted  	 JJ	O
mean  	mean  	 JJ	B-NP
LDL  	LDL  	 NNP	I-NP
cholesterol  	cholesterol  	 NN	I-NP
decreased  	decreased  	 VBD	O
to  	to  	 TO	O
72  	72  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
dL  	dL  	 NN	I-NP
in  	in  	 IN	O
atorvastatin-treated  	atorvastatin-treated  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
but  	but  	 CC	O
increased  	increased  	 VBN	O
to  	to  	 TO	O
135  	135  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
dL  	dL  	 NN	I-NP
among  	among  	 IN	O
placebo-treated  	placebo-treated  	 JJ	O
patients 	patients 	 NNS	O
.  	.  	 .	O
No  	No  	 DT	O
serious  	serious  	 JJ	O
adverse  	adverse  	 JJ	O
events  	events  	 NNS	O
occurred  	occurred  	 VBD	O
as  	as  	 IN	O
the  	the  	 DT	O
result  	result  	 NN	O
of  	of  	 IN	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
atorvastatin 	atorvastatin 	 NN	B-NP
,  	,  	 ,	O
although  	although  	 IN	O
reversible  	reversible  	 JJ	O
liver  	liver  	 NN	B-NP
transaminase  	transaminase  	 NNS	I-NP
elevation  	elevation  	 VBP	I-NP
more  	more  	 JJR	O
than  	than  	 IN	O
three  	three  	 CD	O
times  	times  	 NNS	O
the  	the  	 DT	O
upper  	upper  	 JJ	O
limit  	limit  	 NN	O
of  	of  	 IN	O
normal  	normal  	 JJ	B-NP
occurred  	occurred  	 NN	I-NP
in  	in  	 IN	O
2.5 	2.5 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
atorvastatin-treated  	atorvastatin-treated  	 JJ	B-NP
versus  	versus  	 IN	O
0.6 	0.6 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
placebo-treated  	placebo-treated  	 JJ	O
patients  	patients  	 NNS	O
( 	( 	 -LRB-	O
p  	p  	 FW	O
< 	< 	 SYM	O
0.001 	0.001 	 FW	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
MIRACuLous  	MIRACuLous  	 JJ	O
The  	The  	 DT	O
efficacy  	efficacy  	 NN	O
and  	and  	 CC	O
safety  	safety  	 NN	O
findings  	findings  	 NNS	O
from  	from  	 IN	O
MIRACL  	MIRACL  	 NNP	B-NP
were  	were  	 VBD	O
unique  	unique  	 JJ	O
for  	for  	 IN	O
a  	a  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
reasons 	reasons 	 NNS	O
.  	.  	 .	O
Although  	Although  	 IN	O
lipid-lowering  	lipid-lowering  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
was  	was  	 VBD	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
significantly  	significantly  	 RB	O
lower  	lower  	 JJR	O
mortality  	mortality  	 NN	O
when  	when  	 WRB	O
initiated  	initiated  	 VBN	O
early  	early  	 RB	O
after  	after  	 IN	O
an  	an  	 DT	O
acute  	acute  	 JJ	B-NP
coronary  	coronary  	 JJ	I-NP
syndrome  	syndrome  	 NN	I-NP
in  	in  	 IN	O
two  	two  	 CD	O
large  	large  	 JJ	O
observational  	observational  	 JJ	B-NP
studies  	studies  	 NNS	I-NP
[  	[  	 -LRB-	O
6  	6  	 CD	O
7  	7  	 CD	O
]  	]  	 -RRB-	O
,  	,  	 ,	O
MIRACL  	MIRACL  	 NNP	B-NP
was  	was  	 VBD	O
the  	the  	 DT	O
first  	first  	 JJ	O
randomized  	randomized  	 JJ	B-NP
trial  	trial  	 NN	I-NP
to  	to  	 TO	O
suggest  	suggest  	 VB	O
that  	that  	 IN	O
statins  	statins  	 NNS	B-NP
confer  	confer  	 VBP	O
clinical  	clinical  	 JJ	B-NP
benefits  	benefits  	 NNS	I-NP
in  	in  	 IN	O
this  	this  	 DT	O
setting 	setting 	 NN	O
.  	.  	 .	O
It  	It  	 PRP	O
was  	was  	 VBD	O
also  	also  	 RB	O
the  	the  	 DT	O
first  	first  	 JJ	O
trial  	trial  	 NN	O
to  	to  	 TO	O
identify  	identify  	 VB	O
a  	a  	 DT	O
short-term  	short-term  	 JJ	O
( 	( 	 -LRB-	O
ie 	ie 	 UH	B-NP
,  	,  	 ,	O
within  	within  	 IN	O
16  	16  	 CD	O
weeks 	weeks 	 NNS	O
)  	)  	 -RRB-	O
clinical  	clinical  	 JJ	B-NP
benefit  	benefit  	 NN	I-NP
from  	from  	 IN	O
statin  	statin  	 JJ	B-NP
therapy 	therapy 	 NN	I-NP
;  	;  	 :	O
in  	in  	 IN	O
previous  	previous  	 JJ	O
secondary  	secondary  	 JJ	B-NP
prevention  	prevention  	 NN	I-NP
trials 	trials 	 NNS	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
benefit  	benefit  	 NN	O
of  	of  	 IN	O
statin  	statin  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
was  	was  	 VBD	O
not  	not  	 RB	O
evident  	evident  	 JJ	O
for  	for  	 IN	O
one  	one  	 CD	O
to  	to  	 TO	O
two  	two  	 CD	O
years 	years 	 NNS	O
.  	.  	 .	O
And 	And 	 CC	O
,  	,  	 ,	O
while  	while  	 IN	O
clinical  	clinical  	 JJ	B-NP
trial  	trial  	 NN	I-NP
safety  	safety  	 NN	I-NP
endpoints  	endpoints  	 NNS	I-NP
may  	may  	 MD	O
be  	be  	 VB	O
considered  	considered  	 VBN	O
less  	less  	 RBR	O
glamorous 	glamorous 	 JJ	O
,  	,  	 ,	O
MIRACL 	MIRACL 	 NNP	O
's  	's  	 POS	O
most  	most  	 RBS	O
important  	important  	 JJ	O
contribution  	contribution  	 NN	B-NP
may  	may  	 MD	O
have  	have  	 VB	O
been  	been  	 VBN	O
that  	that  	 IN	O
high-dose  	high-dose  	 JJ	B-NP
statin  	statin  	 JJ	I-NP
therapy  	therapy  	 NN	I-NP
was  	was  	 VBD	O
not  	not  	 RB	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
serious  	serious  	 JJ	B-NP
harm 	harm 	 NN	I-NP
,  	,  	 ,	O
despite  	despite  	 IN	O
its  	its  	 PRP$	O
use  	use  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
unstable  	unstable  	 JJ	O
setting 	setting 	 NN	O
.  	.  	 .	O
Earlier  	Earlier  	 RBR	O
secondary  	secondary  	 JJ	B-NP
prevention  	prevention  	 NN	I-NP
statin  	statin  	 NN	I-NP
trials  	trials  	 NNS	I-NP
had  	had  	 VBD	O
excluded  	excluded  	 VBN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
unstable  	unstable  	 JJ	O
coronary  	coronary  	 NNS	B-NP
syndromes  	syndromes  	 VBP	I-NP
largely  	largely  	 RB	O
out  	out  	 RB	O
of  	of  	 IN	O
theoretical  	theoretical  	 JJ	B-NP
concern  	concern  	 NN	I-NP
that  	that  	 IN	O
statin-mediated  	statin-mediated  	 JJ	B-NP
reductions  	reductions  	 NNS	I-NP
in  	in  	 IN	O
vascular  	vascular  	 JJ	B-NP
smooth  	smooth  	 JJ	I-NP
muscle  	muscle  	 NN	I-NP
cell  	cell  	 NN	I-NP
proliferation  	proliferation  	 NN	I-NP
might  	might  	 MD	O
destabilize  	destabilize  	 VB	O
healing  	healing  	 JJ	O
plaque 	plaque 	 NN	O
.  	.  	 .	O
That  	That  	 IN	O
no  	no  	 DT	O
harm  	harm  	 NN	O
resulted  	resulted  	 VBD	O
from  	from  	 IN	O
this  	this  	 DT	O
aggressive  	aggressive  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
strategy  	strategy  	 NN	I-NP
should  	should  	 MD	O
allay  	allay  	 VB	O
theoretical  	theoretical  	 JJ	B-NP
fears  	fears  	 NNS	I-NP
and  	and  	 CC	O
by  	by  	 IN	O
doing  	doing  	 VBG	O
so  	so  	 RB	O
remove  	remove  	 VB	O
a  	a  	 DT	O
major  	major  	 JJ	O
obstacle  	obstacle  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
inpatient  	inpatient  	 JJ	B-NP
initiation  	initiation  	 NN	I-NP
of  	of  	 IN	I-NP
lipid-lowing  	lipid-lowing  	 JJ	I-NP
therapy  	therapy  	 NN	I-NP
after  	after  	 IN	O
coronary  	coronary  	 JJ	B-NP
events 	events 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
not  	not  	 RB	O
so  	so  	 RB	O
MIRACuLous  	MIRACuLous  	 JJ	O
Despite  	Despite  	 IN	O
these  	these  	 DT	O
unique  	unique  	 JJ	O
and  	and  	 CC	O
important  	important  	 JJ	O
findings 	findings 	 NNS	O
,  	,  	 ,	O
there  	there  	 EX	O
were  	were  	 VBD	O
a  	a  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
inherent  	inherent  	 JJ	O
study  	study  	 NN	B-NP
limitations  	limitations  	 NNS	I-NP
worth  	worth  	 IN	O
noting 	noting 	 VBG	O
.  	.  	 .	O
First  	First  	 NNP	O
and  	and  	 CC	O
foremost 	foremost 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
possibility  	possibility  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
null  	null  	 JJ	O
treatment  	treatment  	 NN	B-NP
effect  	effect  	 NN	I-NP
cannot  	cannot  	 RB	O
be  	be  	 VB	O
ignored  	ignored  	 VBN	O
given  	given  	 VBN	O
the  	the  	 DT	O
wide  	wide  	 JJ	O
confidence  	confidence  	 NN	B-NP
intervals  	intervals  	 NNS	I-NP
( 	( 	 -LRB-	O
and  	and  	 CC	O
hence  	hence  	 RB	O
marginally  	marginally  	 RB	O
significant  	significant  	 JJ	O
p  	p  	 JJ	B-NP
value  	value  	 NN	I-NP
of  	of  	 IN	O
0.048 	0.048 	 CD	O
)  	)  	 -RRB-	O
for  	for  	 IN	O
the  	the  	 DT	O
effect  	effect  	 NN	O
of  	of  	 IN	O
atorvastatin  	atorvastatin  	 NN	B-NP
on  	on  	 IN	O
the  	the  	 DT	O
primary  	primary  	 JJ	B-NP
efficacy  	efficacy  	 JJ	I-NP
endpoint 	endpoint 	 NN	I-NP
.  	.  	 .	O
Furthermore 	Furthermore 	 RB	O
,  	,  	 ,	O
while  	while  	 IN	O
the  	the  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
lost  	lost  	 VBD	O
to  	to  	 TO	O
follow  	follow  	 VB	O
up  	up  	 RB	O
was  	was  	 VBD	O
small 	small 	 JJ	O
,  	,  	 ,	O
if  	if  	 IN	O
adverse  	adverse  	 JJ	O
events  	events  	 NNS	O
had  	had  	 VBD	O
occurred  	occurred  	 VBN	O
in  	in  	 IN	O
those  	those  	 DT	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
atorvastatin  	atorvastatin  	 NNS	B-NP
( 	( 	 -LRB-	O
n  	n  	 CD	O
=  	=  	 SYM	O
3 	3 	 LS	O
)  	)  	 -RRB-	O
but  	but  	 CC	O
not  	not  	 RB	O
placebo  	placebo  	 JJ	O
( 	( 	 -LRB-	O
n  	n  	 CD	O
=  	=  	 SYM	O
8 	8 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
the  	the  	 DT	O
overall  	overall  	 JJ	O
trial  	trial  	 NN	B-NP
results  	results  	 NNS	I-NP
may  	may  	 MD	O
have  	have  	 VB	O
been  	been  	 VBN	O
neutral  	neutral  	 JJ	O
rather  	rather  	 RB	O
than  	than  	 IN	O
positive 	positive 	 JJ	O
.  	.  	 .	O
The  	The  	 DT	O
types  	types  	 NNS	O
of  	of  	 IN	O
events  	events  	 NNS	O
prevented  	prevented  	 VBN	O
in  	in  	 IN	O
MIRACL  	MIRACL  	 NNP	B-NP
are  	are  	 VBP	O
also  	also  	 RB	O
worth  	worth  	 JJ	O
noting 	noting 	 NN	O
.  	.  	 .	O
While  	While  	 IN	O
rehospitalization  	rehospitalization  	 NN	B-NP
for  	for  	 IN	O
recurrent  	recurrent  	 JJ	O
myocardial  	myocardial  	 JJ	B-NP
ischemia  	ischemia  	 NN	I-NP
is  	is  	 VBZ	O
an  	an  	 DT	O
important  	important  	 JJ	O
determinant  	determinant  	 NN	B-NP
of  	of  	 IN	O
quality  	quality  	 NN	O
of  	of  	 IN	O
life  	life  	 NN	O
and  	and  	 CC	O
health  	health  	 NN	B-NP
care  	care  	 NN	I-NP
costs 	costs 	 NNS	I-NP
,  	,  	 ,	O
other  	other  	 JJ	O
important  	important  	 JJ	O
endpoints  	endpoints  	 NN	B-NP
were  	were  	 VBD	O
not  	not  	 RB	O
significantly  	significantly  	 RB	O
affected  	affected  	 VBN	O
( 	( 	 -LRB-	O
eg 	eg 	 UH	B-NP
,  	,  	 ,	O
death 	death 	 NN	O
,  	,  	 ,	O
myocardial  	myocardial  	 JJ	B-NP
infarction 	infarction 	 NN	I-NP
,  	,  	 ,	O
resuscitated  	resuscitated  	 JJ	O
sudden  	sudden  	 JJ	O
cardiac  	cardiac  	 JJ	B-NP
death 	death 	 NN	I-NP
,  	,  	 ,	O
worsening  	worsening  	 VBG	B-NP
heart  	heart  	 NN	I-NP
failure 	failure 	 NN	I-NP
,  	,  	 ,	O
need  	need  	 VBP	O
for  	for  	 IN	O
coronary  	coronary  	 JJ	B-NP
revascularization 	revascularization 	 NN	I-NP
,  	,  	 ,	O
etc 	etc 	 FW	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
question  	question  	 NN	O
of  	of  	 IN	O
whether  	whether  	 IN	O
statins  	statins  	 NNS	B-NP
can  	can  	 MD	O
prevent  	prevent  	 VB	O
these  	these  	 DT	O
and  	and  	 CC	O
other  	other  	 JJ	O
adverse  	adverse  	 JJ	O
events  	events  	 NNS	O
when  	when  	 WRB	O
initiated  	initiated  	 VBN	O
soon  	soon  	 RB	O
after  	after  	 IN	O
an  	an  	 DT	O
acute  	acute  	 JJ	B-NP
coronary  	coronary  	 JJ	I-NP
syndrome  	syndrome  	 NN	I-NP
will  	will  	 MD	O
require  	require  	 VB	O
further  	further  	 JJ	O
study 	study 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
short  	short  	 JJ	O
duration  	duration  	 NN	O
of  	of  	 IN	O
follow-up  	follow-up  	 NNP	O
is  	is  	 VBZ	O
also  	also  	 RB	O
particularly  	particularly  	 RB	O
troubling 	troubling 	 JJ	O
.  	.  	 .	O
While  	While  	 IN	O
it  	it  	 PRP	O
is  	is  	 VBZ	O
impressive  	impressive  	 JJ	O
that  	that  	 IN	O
a  	a  	 DT	O
clinical  	clinical  	 JJ	B-NP
benefit  	benefit  	 NN	I-NP
was  	was  	 VBD	O
realized  	realized  	 VBN	O
after  	after  	 IN	O
only  	only  	 RB	O
16  	16  	 CD	O
weeks  	weeks  	 NNS	O
of  	of  	 IN	O
statin  	statin  	 JJ	B-NP
therapy 	therapy 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
increased  	increased  	 JJ	O
risk  	risk  	 NN	O
of  	of  	 IN	O
adverse  	adverse  	 JJ	O
clinical  	clinical  	 JJ	B-NP
events  	events  	 NNS	I-NP
persists  	persists  	 VBZ	O
throughout  	throughout  	 IN	O
the  	the  	 DT	O
year  	year  	 NN	O
following  	following  	 VBG	O
an  	an  	 DT	O
acute  	acute  	 JJ	B-NP
coronary  	coronary  	 JJ	I-NP
syndrome 	syndrome 	 NN	I-NP
.  	.  	 .	O
Without  	Without  	 IN	O
longer  	longer  	 JJR	O
clinical  	clinical  	 NNS	O
follow  	follow  	 VBP	O
up 	up 	 RB	O
,  	,  	 ,	O
it  	it  	 PRP	O
is  	is  	 VBZ	O
not  	not  	 RB	O
possible  	possible  	 JJ	O
to  	to  	 TO	O
assess  	assess  	 VB	O
the  	the  	 DT	O
intermediate-term  	intermediate-term  	 JJ	B-NP
effect  	effect  	 NN	I-NP
( 	( 	 -LRB-	O
if  	if  	 IN	O
any 	any 	 DT	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
atorvastatin  	atorvastatin  	 NN	B-NP
on  	on  	 IN	O
hard  	hard  	 JJ	O
endpoints  	endpoints  	 JJ	O
such  	such  	 JJ	O
as  	as  	 IN	O
death  	death  	 NN	O
or  	or  	 CC	O
myocardial  	myocardial  	 JJ	B-NP
infarction 	infarction 	 NN	I-NP
.  	.  	 .	O
To  	To  	 TO	O
do  	do  	 VB	O
so  	so  	 RB	O
would  	would  	 MD	O
be  	be  	 VB	O
critical  	critical  	 JJ	O
in  	in  	 IN	O
light  	light  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
lack  	lack  	 NN	O
of  	of  	 IN	O
effect  	effect  	 NN	O
on  	on  	 IN	O
these  	these  	 DT	O
important  	important  	 JJ	O
endpoints  	endpoints  	 NN	B-NP
at  	at  	 IN	O
16  	16  	 CD	O
weeks 	weeks 	 NNS	O
.  	.  	 .	O
Unfortunately 	Unfortunately 	 RB	O
,  	,  	 ,	O
no  	no  	 DT	O
late  	late  	 JJ	O
clinical  	clinical  	 NNS	O
follow  	follow  	 VBP	O
up  	up  	 RB	O
is  	is  	 VBZ	O
planned 	planned 	 VBN	O
.  	.  	 .	O
There  	There  	 EX	O
were  	were  	 VBD	O
also  	also  	 RB	O
a  	a  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
limitations  	limitations  	 NNS	O
that  	that  	 WDT	O
may  	may  	 MD	O
have  	have  	 VB	O
hampered  	hampered  	 VBN	O
the  	the  	 DT	O
study 	study 	 NN	O
's  	's  	 POS	O
generalizability 	generalizability 	 NN	B-NP
.  	.  	 .	O
First 	First 	 NNP	O
,  	,  	 ,	O
patients  	patients  	 NNS	O
who  	who  	 WP	O
underwent  	underwent  	 VBD	O
recent  	recent  	 JJ	O
revascularization  	revascularization  	 NN	B-NP
or  	or  	 CC	O
in  	in  	 IN	O
whom  	whom  	 WP	O
it  	it  	 PRP	O
was  	was  	 VBD	O
planned  	planned  	 VBN	O
were  	were  	 VBD	O
excluded 	excluded 	 VBN	O
.  	.  	 .	O
Specifically 	Specifically 	 RB	O
,  	,  	 ,	O
patients  	patients  	 NNS	O
who  	who  	 WP	O
underwent  	underwent  	 VBD	O
percutaneous  	percutaneous  	 FW	B-NP
transluminal  	transluminal  	 FW	I-NP
coronary  	coronary  	 FW	I-NP
angioplasty  	angioplasty  	 FW	I-NP
( 	( 	 -LRB-	O
PTCA 	PTCA 	 NNP	B-NP
)  	)  	 -RRB-	O
or  	or  	 CC	O
coronary  	coronary  	 FW	B-NP
artery  	artery  	 FW	I-NP
bypass  	bypass  	 FW	I-NP
graft  	graft  	 FW	I-NP
( 	( 	 -LRB-	O
CABG 	CABG 	 NNP	B-NP
)  	)  	 -RRB-	O
surgery  	surgery  	 NN	O
within  	within  	 IN	O
the  	the  	 DT	O
previous  	previous  	 JJ	O
three  	three  	 CD	O
or  	or  	 CC	O
six  	six  	 CD	O
months  	months  	 NNS	O
respectively  	respectively  	 RB	O
were  	were  	 VBD	O
not  	not  	 RB	O
eligible  	eligible  	 JJ	O
for  	for  	 IN	O
inclusion 	inclusion 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
investigators  	investigators  	 NNS	B-NP
reasoned  	reasoned  	 VBD	O
that  	that  	 DT	O
recurrent  	recurrent  	 JJ	O
ischemic  	ischemic  	 JJ	B-NP
events  	events  	 NNS	I-NP
in  	in  	 IN	O
this  	this  	 DT	O
population  	population  	 NN	O
were  	were  	 VBD	O
likely  	likely  	 JJ	O
to  	to  	 TO	O
result  	result  	 VB	O
from  	from  	 IN	O
restenosis  	restenosis  	 NN	B-NP
or  	or  	 CC	O
bypass  	bypass  	 VB	O
graft  	graft  	 JJ	O
closure  	closure  	 NN	O
and  	and  	 CC	O
that  	that  	 DT	O
statins  	statins  	 NN	B-NP
would  	would  	 MD	O
be  	be  	 VB	O
less  	less  	 RBR	O
likely  	likely  	 JJ	O
to  	to  	 TO	O
affect  	affect  	 VB	O
these  	these  	 DT	O
processes  	processes  	 NNS	O
[  	[  	 -LRB-	O
8  	8  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
Nevertheless 	Nevertheless 	 RB	O
,  	,  	 ,	O
a  	a  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
trials  	trials  	 NNS	O
have  	have  	 VBP	O
established  	established  	 VBN	O
the  	the  	 DT	O
benefits  	benefits  	 NNS	O
of  	of  	 IN	O
statin  	statin  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
early  	early  	 RB	O
after  	after  	 IN	O
coronary  	coronary  	 JJ	B-NP
revascularization  	revascularization  	 NNS	I-NP
[  	[  	 -LRB-	O
9  	9  	 CD	O
10  	10  	 CD	O
11  	11  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
Furthermore 	Furthermore 	 RB	O
,  	,  	 ,	O
a  	a  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
recent  	recent  	 JJ	O
trials  	trials  	 NNS	O
have  	have  	 VBP	O
suggested  	suggested  	 VBN	O
that  	that  	 IN	O
higher  	higher  	 JJR	O
risk  	risk  	 NN	B-NP
patients  	patients  	 NNS	I-NP
with  	with  	 IN	O
non-ST  	non-ST  	 FW	B-NP
elevation  	elevation  	 FW	I-NP
acute  	acute  	 FW	I-NP
coronary  	coronary  	 FW	I-NP
syndromes  	syndromes  	 FW	I-NP
fair  	fair  	 JJ	O
better  	better  	 JJR	O
when  	when  	 WRB	O
an  	an  	 DT	O
early  	early  	 JJ	O
invasive  	invasive  	 JJ	B-NP
strategy  	strategy  	 NN	I-NP
is  	is  	 VBZ	O
applied  	applied  	 VBN	O
[  	[  	 -LRB-	O
12  	12  	 CD	O
13  	13  	 CD	O
14  	14  	 CD	O
]  	]  	 -RRB-	O
and  	and  	 CC	O
it  	it  	 PRP	O
is  	is  	 VBZ	O
not  	not  	 RB	O
uncommon  	uncommon  	 JJ	O
for  	for  	 IN	O
patients  	patients  	 NNS	O
to  	to  	 TO	O
be  	be  	 VB	O
treated  	treated  	 VBN	O
in  	in  	 IN	O
this  	this  	 DT	O
fashion 	fashion 	 NN	O
.  	.  	 .	O
Second 	Second 	 LS	O
,  	,  	 ,	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
Q-wave  	Q-wave  	 JJ	B-NP
myocardial  	myocardial  	 JJ	I-NP
infarction  	infarction  	 NN	I-NP
were  	were  	 VBD	O
not  	not  	 RB	O
eligible  	eligible  	 JJ	O
for  	for  	 IN	O
enrollment  	enrollment  	 NN	O
because  	because  	 IN	O
it  	it  	 PRP	O
was  	was  	 VBD	O
felt  	felt  	 VBN	O
that  	that  	 IN	O
statins  	statins  	 NNS	B-NP
would  	would  	 MD	O
not  	not  	 RB	O
influence  	influence  	 VB	O
the  	the  	 DT	O
development  	development  	 NN	O
of  	of  	 IN	O
important  	important  	 JJ	O
prognostic  	prognostic  	 NNS	B-NP
determinants  	determinants  	 VBP	I-NP
such  	such  	 JJ	O
as  	as  	 IN	O
left  	left  	 VBN	O
ventricular  	ventricular  	 JJ	B-NP
systolic  	systolic  	 JJ	I-NP
dysfunction 	dysfunction 	 NN	I-NP
,  	,  	 ,	O
ventricular  	ventricular  	 JJ	B-NP
arrhythmias  	arrhythmias  	 NN	I-NP
or  	or  	 CC	O
mechanical  	mechanical  	 JJ	B-NP
complications  	complications  	 NNS	I-NP
[  	[  	 -LRB-	O
5  	5  	 LS	O
]  	]  	 -RRB-	O
.  	.  	 .	O
Nevertheless 	Nevertheless 	 RB	O
,  	,  	 ,	O
patients  	patients  	 NNS	O
who  	who  	 WP	O
develop  	develop  	 VBP	O
electrocardiographic  	electrocardiographic  	 JJ	B-NP
Q-waves  	Q-waves  	 NNS	I-NP
represent  	represent  	 VBP	O
a  	a  	 DT	O
substantial  	substantial  	 JJ	O
proportion  	proportion  	 NN	O
of  	of  	 IN	O
all  	all  	 DT	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
myocardial  	myocardial  	 JJ	B-NP
infarction 	infarction 	 NN	I-NP
.  	.  	 .	O
While  	While  	 IN	O
their  	their  	 PRP$	O
short-term  	short-term  	 JJ	O
risk  	risk  	 NN	O
following  	following  	 VBG	O
hospital  	hospital  	 NN	B-NP
discharge  	discharge  	 NN	I-NP
is  	is  	 VBZ	O
lower  	lower  	 RBR	O
relative  	relative  	 JJ	O
to  	to  	 TO	O
those  	those  	 DT	O
with  	with  	 IN	O
a  	a  	 DT	O
non-Q-wave  	non-Q-wave  	 JJ	B-NP
myocardial  	myocardial  	 JJ	I-NP
infarction 	infarction 	 NN	I-NP
,  	,  	 ,	O
it  	it  	 PRP	O
is  	is  	 VBZ	O
still  	still  	 RB	O
much  	much  	 RB	O
greater  	greater  	 JJR	O
than  	than  	 IN	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
stable  	stable  	 JJ	O
coronary  	coronary  	 JJ	B-NP
disease 	disease 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
need  	need  	 NN	O
for  	for  	 IN	O
secondary  	secondary  	 JJ	B-NP
prevention  	prevention  	 NN	I-NP
in  	in  	 IN	O
this  	this  	 DT	O
population  	population  	 NN	O
is  	is  	 VBZ	O
equally  	equally  	 RB	O
important 	important 	 JJ	O
.  	.  	 .	O
Third 	Third 	 JJ	O
,  	,  	 ,	O
despite  	despite  	 IN	O
the  	the  	 DT	O
high  	high  	 JJ	O
risk  	risk  	 NN	B-NP
nature  	nature  	 NN	I-NP
of  	of  	 IN	O
enrolled  	enrolled  	 JJ	O
patients  	patients  	 NNS	O
( 	( 	 -LRB-	O
ie 	ie 	 UH	B-NP
,  	,  	 ,	O
electrocardiogram  	electrocardiogram  	 NNS	B-NP
[ 	[ 	 -LRB-	O
ECG 	ECG 	 NNP	B-NP
]  	]  	 -RRB-	O
changes  	changes  	 NNS	O
and 	and 	 CC	O
/ 	/ 	 NNP	O
or  	or  	 CC	O
other  	other  	 JJ	O
objective  	objective  	 NN	B-NP
evidence  	evidence  	 NN	I-NP
of  	of  	 IN	I-NP
ischemia 	ischemia 	 CD	I-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
the  	the  	 DT	O
rate  	rate  	 NN	O
of  	of  	 IN	O
platelet  	platelet  	 FW	B-NP
glycoprotein  	glycoprotein  	 FW	I-NP
IIb 	IIb 	 FW	I-NP
/ 	/ 	 FW	I-NP
IIIa  	IIIa  	 FW	I-NP
inhibitor  	inhibitor  	 FW	I-NP
utilization  	utilization  	 NN	I-NP
was  	was  	 VBD	O
quite  	quite  	 RB	O
low  	low  	 JJ	O
( 	( 	 -LRB-	O
1.1 	1.1 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Such  	Such  	 JJ	O
therapy  	therapy  	 NN	O
appears  	appears  	 VBZ	O
to  	to  	 TO	O
be  	be  	 VB	O
cost  	cost  	 VBN	O
effective  	effective  	 JJ	O
[  	[  	 -LRB-	O
15  	15  	 CD	O
16  	16  	 CD	O
]  	]  	 -RRB-	O
,  	,  	 ,	O
especially  	especially  	 RB	O
among  	among  	 IN	O
high  	high  	 JJ	O
risk  	risk  	 NN	B-NP
patients  	patients  	 NNS	I-NP
and  	and  	 CC	O
is  	is  	 VBZ	O
recommended  	recommended  	 VBN	O
under  	under  	 IN	O
current  	current  	 JJ	O
American  	American  	 NNP	O
College  	College  	 NNP	O
of  	of  	 IN	O
Cardiology 	Cardiology 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
American  	American  	 NNP	I-NP
Heart  	Heart  	 NNP	I-NP
Association  	Association  	 NNP	I-NP
guidelines  	guidelines  	 NNS	I-NP
[  	[  	 -LRB-	O
17  	17  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
Fourth 	Fourth 	 JJ	O
,  	,  	 ,	O
it  	it  	 PRP	O
may  	may  	 MD	O
not  	not  	 RB	O
be  	be  	 VB	O
possible  	possible  	 JJ	O
to  	to  	 TO	O
ascertain  	ascertain  	 VB	O
whether  	whether  	 IN	O
these  	these  	 DT	O
findings  	findings  	 NNS	O
apply  	apply  	 VBP	O
to  	to  	 TO	O
all  	all  	 DT	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
recent  	recent  	 JJ	O
acute  	acute  	 JJ	B-NP
coronary  	coronary  	 NNS	I-NP
syndromes  	syndromes  	 VBP	I-NP
regardless  	regardless  	 RB	O
of  	of  	 IN	O
baseline  	baseline  	 JJ	B-NP
lipid  	lipid  	 NN	I-NP
levels 	levels 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
small  	small  	 JJ	O
difference  	difference  	 NN	O
in  	in  	 IN	O
number  	number  	 NN	O
of  	of  	 IN	O
primary  	primary  	 JJ	B-NP
endpoint  	endpoint  	 JJ	I-NP
events  	events  	 NNS	I-NP
between  	between  	 IN	O
atorvastatin  	atorvastatin  	 NN	B-NP
and  	and  	 CC	O
placebo  	placebo  	 JJ	O
groups  	groups  	 NNS	O
make  	make  	 VBP	O
it  	it  	 PRP	O
difficult  	difficult  	 JJ	O
to  	to  	 TO	O
dissect  	dissect  	 VB	O
the  	the  	 DT	O
relationship  	relationship  	 NN	B-NP
between  	between  	 IN	O
baseline  	baseline  	 JJ	B-NP
lipid  	lipid  	 NN	I-NP
levels  	levels  	 NNS	I-NP
and  	and  	 CC	O
treatment  	treatment  	 NN	B-NP
effect  	effect  	 NN	I-NP
further 	further 	 RBR	O
.  	.  	 .	O
Consequently 	Consequently 	 RB	O
,  	,  	 ,	O
it  	it  	 PRP	O
remains  	remains  	 VBZ	O
uncertain  	uncertain  	 JJ	O
whether  	whether  	 IN	O
one  	one  	 PRP	O
can  	can  	 MD	O
extrapolate  	extrapolate  	 VB	O
the  	the  	 DT	O
MIRACL  	MIRACL  	 NNP	B-NP
trial  	trial  	 NN	I-NP
results  	results  	 NNS	I-NP
to  	to  	 TO	O
those  	those  	 DT	O
who  	who  	 WP	O
undergo  	undergo  	 VBP	O
coronary  	coronary  	 JJ	B-NP
revascularization  	revascularization  	 NNS	I-NP
shortly  	shortly  	 RB	O
before  	before  	 RB	O
or  	or  	 CC	O
after  	after  	 IN	O
a  	a  	 DT	O
coronary  	coronary  	 JJ	B-NP
event 	event 	 NN	I-NP
,  	,  	 ,	O
who  	who  	 WP	O
present  	present  	 VBP	O
with  	with  	 IN	O
a  	a  	 DT	O
Q-wave  	Q-wave  	 JJ	B-NP
myocardial  	myocardial  	 JJ	I-NP
infarction 	infarction 	 NN	I-NP
,  	,  	 ,	O
who  	who  	 WP	O
are  	are  	 VBP	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
platelet  	platelet  	 FW	B-NP
glycoprotein  	glycoprotein  	 FW	I-NP
IIb 	IIb 	 FW	I-NP
/ 	/ 	 FW	I-NP
IIIa  	IIIa  	 FW	I-NP
inhibitors 	inhibitors 	 FW	I-NP
,  	,  	 ,	O
or  	or  	 CC	O
who  	who  	 WP	O
have  	have  	 VBP	O
relatively  	relatively  	 RB	O
low  	low  	 JJ	O
admission  	admission  	 NN	B-NP
LDL  	LDL  	 NNP	I-NP
cholesterol  	cholesterol  	 NN	I-NP
levels 	levels 	 NNS	I-NP
.  	.  	 .	O
Time  	Time  	 NN	O
to  	to  	 TO	O
change  	change  	 VB	O
current  	current  	 JJ	O
practice  	practice  	 NN	O
Although  	Although  	 IN	O
MIRACL  	MIRACL  	 NNP	B-NP
and  	and  	 CC	O
the  	the  	 DT	O
two  	two  	 CD	O
aforementioned  	aforementioned  	 JJ	B-NP
cohort  	cohort  	 JJ	I-NP
studies  	studies  	 NNS	I-NP
suggest  	suggest  	 VBP	O
that  	that  	 IN	O
lipid-lowering  	lipid-lowering  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
exert  	exert  	 VBP	O
short-term  	short-term  	 JJ	O
clinical  	clinical  	 JJ	B-NP
benefits  	benefits  	 NNS	I-NP
when  	when  	 WRB	O
initiated  	initiated  	 VBN	O
soon  	soon  	 RB	O
after  	after  	 IN	O
an  	an  	 DT	O
acute  	acute  	 JJ	B-NP
coronary  	coronary  	 JJ	I-NP
syndrome 	syndrome 	 NN	I-NP
,  	,  	 ,	O
this  	this  	 DT	O
remains  	remains  	 VBZ	O
an  	an  	 DT	O
open  	open  	 JJ	O
question 	question 	 NN	O
.  	.  	 .	O
Even  	Even  	 RB	O
if  	if  	 IN	O
these  	these  	 DT	O
findings  	findings  	 NNS	O
are  	are  	 VBP	O
not  	not  	 RB	O
confirmed  	confirmed  	 VBN	O
after  	after  	 IN	O
further  	further  	 JJ	O
study 	study 	 NN	O
,  	,  	 ,	O
one  	one  	 PRP	O
could  	could  	 MD	O
still  	still  	 RB	O
make  	make  	 VB	O
a  	a  	 DT	O
compelling  	compelling  	 JJ	O
argument  	argument  	 NN	O
that  	that  	 IN	O
lipid-lowering  	lipid-lowering  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
( 	( 	 -LRB-	O
barring  	barring  	 FW	O
contraindications 	contraindications 	 FW	B-NP
)  	)  	 -RRB-	O
should  	should  	 MD	O
be  	be  	 VB	O
initiated  	initiated  	 VBN	O
early  	early  	 JJ	O
and  	and  	 CC	O
universally  	universally  	 RB	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
who  	who  	 WP	O
present  	present  	 VBP	O
with  	with  	 IN	O
an  	an  	 DT	O
acute  	acute  	 JJ	B-NP
coronary  	coronary  	 JJ	I-NP
syndrome 	syndrome 	 NN	I-NP
:  	:  	 :	O
First 	First 	 NNP	O
,  	,  	 ,	O
the  	the  	 DT	O
long-term  	long-term  	 JJ	O
safety  	safety  	 NN	O
and  	and  	 CC	O
effectiveness  	effectiveness  	 NN	O
of  	of  	 IN	O
statins  	statins  	 NN	B-NP
for  	for  	 IN	I-NP
the  	the  	 DT	I-NP
secondary  	secondary  	 JJ	I-NP
prevention  	prevention  	 NN	I-NP
of  	of  	 IN	O
stable  	stable  	 JJ	O
coronary  	coronary  	 JJ	B-NP
disease  	disease  	 NN	I-NP
is  	is  	 VBZ	O
well-established  	well-established  	 JJ	O
[  	[  	 -LRB-	O
1  	1  	 CD	O
2  	2  	 CD	O
3  	3  	 CD	O
]  	]  	 -RRB-	O
;  	;  	 :	O
Second 	Second 	 LS	O
,  	,  	 ,	O
as  	as  	 RB	O
evidenced  	evidenced  	 VBN	O
by  	by  	 IN	O
MIRACL 	MIRACL 	 NNP	B-NP
,  	,  	 ,	O
these  	these  	 DT	O
agents  	agents  	 NNS	O
are  	are  	 VBP	O
safe  	safe  	 JJ	O
when  	when  	 WRB	O
initiated  	initiated  	 VBN	O
at  	at  	 IN	O
the  	the  	 DT	O
time  	time  	 NN	O
of  	of  	 IN	O
hospitalization  	hospitalization  	 NN	B-NP
for  	for  	 IN	O
an  	an  	 DT	O
acute  	acute  	 JJ	B-NP
coronary  	coronary  	 JJ	I-NP
syndrome 	syndrome 	 NN	I-NP
;  	;  	 :	O
Third 	Third 	 LS	O
,  	,  	 ,	O
the  	the  	 DT	O
in-hospital  	in-hospital  	 JJ	B-NP
initiation  	initiation  	 NN	I-NP
of  	of  	 IN	I-NP
lipid-lowering  	lipid-lowering  	 JJ	I-NP
therapy  	therapy  	 NN	I-NP
appears  	appears  	 VBZ	O
to  	to  	 TO	O
promote  	promote  	 VB	O
greater  	greater  	 JJR	O
long-term  	long-term  	 JJ	O
utilization  	utilization  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
agents  	agents  	 NNS	O
[  	[  	 -LRB-	O
18  	18  	 CD	O
19  	19  	 CD	O
20  	20  	 CD	O
21  	21  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
Finally 	Finally 	 RB	O
,  	,  	 ,	O
although  	although  	 IN	O
lipid  	lipid  	 JJ	B-NP
levels  	levels  	 NNS	I-NP
may  	may  	 MD	O
be  	be  	 VB	O
unreliable  	unreliable  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
setting  	setting  	 NN	O
of  	of  	 IN	O
an  	an  	 DT	O
acute  	acute  	 JJ	B-NP
coronary  	coronary  	 JJ	I-NP
syndrome  	syndrome  	 NN	I-NP
( 	( 	 -LRB-	O
excepting  	excepting  	 JJ	O
total  	total  	 NN	O
: 	: 	 :	O
HDL  	HDL  	 NNP	B-NP
and  	and  	 CC	O
LDL 	LDL 	 NNP	B-NP
: 	: 	 :	O
HDL  	HDL  	 NNP	B-NP
cholesterol  	cholesterol  	 NN	I-NP
ratios  	ratios  	 NNS	I-NP
[  	[  	 -LRB-	O
22  	22  	 CD	O
]  	]  	 CD	O
)  	)  	 -RRB-	O
the  	the  	 DT	O
overwhelming  	overwhelming  	 JJ	O
majority  	majority  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
coronary  	coronary  	 JJ	B-NP
disease  	disease  	 NN	I-NP
will  	will  	 MD	O
ultimately  	ultimately  	 RB	O
require  	require  	 VB	O
both  	both  	 DT	O
pharmacologic  	pharmacologic  	 NN	B-NP
and  	and  	 CC	O
non-pharmacologic  	non-pharmacologic  	 JJ	B-NP
lipid-lowering  	lipid-lowering  	 JJ	I-NP
interventions  	interventions  	 NNS	I-NP
to  	to  	 TO	O
attain  	attain  	 VB	O
recommended  	recommended  	 VBN	B-NP
cholesterol  	cholesterol  	 NN	I-NP
targets  	targets  	 NNS	I-NP
[  	[  	 -LRB-	O
23  	23  	 CD	O
24  	24  	 CD	O
25  	25  	 CD	O
]  	]  	 -RRB-	O
;  	;  	 :	O
newer  	newer  	 JJR	O
guidelines  	guidelines  	 NNS	O
are  	are  	 VBP	O
even  	even  	 RB	O
more  	more  	 RBR	O
stringent  	stringent  	 JJ	O
[  	[  	 -LRB-	O
26  	26  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
Furthermore 	Furthermore 	 RB	O
,  	,  	 ,	O
data  	data  	 NNS	O
from  	from  	 IN	O
the  	the  	 DT	O
recently  	recently  	 RB	O
presented  	presented  	 VBN	B-NP
Heart  	Heart  	 NNP	I-NP
Protection  	Protection  	 NNP	I-NP
Study  	Study  	 NNP	I-NP
suggest  	suggest  	 VBP	O
that  	that  	 IN	O
clinical  	clinical  	 JJ	B-NP
benefits  	benefits  	 NNS	I-NP
may  	may  	 MD	O
accrue  	accrue  	 VB	O
independent  	independent  	 JJ	O
of  	of  	 IN	O
baseline  	baseline  	 JJ	B-NP
cholesterol  	cholesterol  	 NN	I-NP
level  	level  	 NN	I-NP
[  	[  	 -LRB-	O
4  	4  	 LS	O
]  	]  	 -RRB-	O
.  	.  	 .	O
Thus 	Thus 	 RB	O
,  	,  	 ,	O
to  	to  	 TO	O
withhold  	withhold  	 VB	O
lipid-lowering  	lipid-lowering  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
from  	from  	 IN	O
patients  	patients  	 NNS	O
who  	who  	 WP	O
present  	present  	 VBP	O
with  	with  	 IN	O
an  	an  	 DT	O
acute  	acute  	 JJ	B-NP
coronary  	coronary  	 JJ	I-NP
syndrome  	syndrome  	 NN	I-NP
would  	would  	 MD	O
be  	be  	 VB	O
to  	to  	 TO	O
accept  	accept  	 VB	O
the  	the  	 DT	O
status  	status  	 FW	B-NP
quo 	quo 	 FW	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
to  	to  	 TO	O
date  	date  	 VB	O
our  	our  	 PRP$	O
efforts  	efforts  	 NNS	O
at  	at  	 IN	O
cholesterol  	cholesterol  	 NN	B-NP
lowering  	lowering  	 VBG	O
in  	in  	 IN	O
the  	the  	 DT	O
secondary  	secondary  	 JJ	B-NP
prevention  	prevention  	 NN	I-NP
setting  	setting  	 NNS	I-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
dismal  	dismal  	 JJ	O
[  	[  	 -LRB-	O
27  	27  	 CD	O
28  	28  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
More  	More  	 RBR	O
MIRACLes  	MIRACLes  	 JJ	O
ahead 	ahead 	 RB	O
?  	?  	 .	O
The  	The  	 DT	O
ascertainment  	ascertainment  	 NN	B-NP
and  	and  	 CC	O
quantification  	quantification  	 NN	B-NP
of  	of  	 IN	O
any  	any  	 DT	O
incremental  	incremental  	 JJ	B-NP
benefit  	benefit  	 NN	I-NP
conferred  	conferred  	 NN	I-NP
by  	by  	 IN	O
statin  	statin  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
initiated  	initiated  	 VBD	O
early  	early  	 RB	O
after  	after  	 IN	O
an  	an  	 DT	O
acute  	acute  	 JJ	B-NP
coronary  	coronary  	 JJ	I-NP
syndrome  	syndrome  	 NN	I-NP
will  	will  	 MD	O
require  	require  	 VB	O
confirmation 	confirmation 	 NN	B-NP
.  	.  	 .	O
There  	There  	 EX	O
is  	is  	 VBZ	O
currently  	currently  	 RB	O
only  	only  	 RB	O
one  	one  	 CD	O
ongoing  	ongoing  	 JJ	O
randomized  	randomized  	 JJ	B-NP
placebo-controlled  	placebo-controlled  	 JJ	I-NP
trial  	trial  	 NN	I-NP
of  	of  	 IN	O
early  	early  	 JJ	O
versus  	versus  	 NNS	O
delayed  	delayed  	 VBN	O
statin  	statin  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
in  	in  	 IN	O
this  	this  	 DT	O
setting 	setting 	 NN	O
,  	,  	 ,	O
A-2-Z  	A-2-Z  	 NNP	B-NP
( 	( 	 -LRB-	O
Aggrastat  	Aggrastat  	 NNP	B-NP
to  	to  	 TO	O
Zocor 	Zocor 	 NNP	B-NP
,  	,  	 ,	O
Merck 	Merck 	 NNP	O
)  	)  	 -RRB-	O
[  	[  	 -LRB-	O
29  	29  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
A-2-Z  	A-2-Z  	 JJ	B-NP
study  	study  	 NN	I-NP
is  	is  	 VBZ	O
evaluating  	evaluating  	 VBG	O
the  	the  	 DT	O
efficacy  	efficacy  	 NN	O
of  	of  	 IN	O
early  	early  	 JJ	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
simvastatin  	simvastatin  	 NN	B-NP
in  	in  	 IN	O
4,500  	4,500  	 CD	O
patients  	patients  	 NNS	O
following  	following  	 VBG	O
an  	an  	 DT	O
episode  	episode  	 NN	O
of  	of  	 IN	O
unstable  	unstable  	 JJ	O
angina  	angina  	 NN	O
or  	or  	 CC	O
a  	a  	 DT	O
non-Q  	non-Q  	 JJ	B-NP
wave  	wave  	 NN	I-NP
myocardial  	myocardial  	 NN	I-NP
infarction 	infarction 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
first  	first  	 JJ	O
four  	four  	 CD	O
months 	months 	 NNS	O
,  	,  	 ,	O
patients  	patients  	 NNS	O
will  	will  	 MD	O
be  	be  	 VB	O
randomized  	randomized  	 VBN	O
to  	to  	 TO	O
simvastatin  	simvastatin  	 CD	B-NP
40  	40  	 CD	O
mg  	mg  	 CD	B-NP
daily  	daily  	 JJ	O
or  	or  	 CC	O
placebo 	placebo 	 NN	O
.  	.  	 .	O
Thereafter 	Thereafter 	 RB	O
,  	,  	 ,	O
those  	those  	 DT	O
patients  	patients  	 NNS	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
simvastatin  	simvastatin  	 NN	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
first  	first  	 JJ	O
phase  	phase  	 NN	O
will  	will  	 MD	O
receive  	receive  	 VB	O
80  	80  	 CD	O
mg  	mg  	 NN	B-NP
of  	of  	 IN	I-NP
simvastatin  	simvastatin  	 JJ	I-NP
daily  	daily  	 JJ	I-NP
and  	and  	 CC	O
those  	those  	 DT	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
placebo 	placebo 	 NN	O
,  	,  	 ,	O
40  	40  	 CD	O
mg  	mg  	 NN	B-NP
of  	of  	 IN	I-NP
simvastatin  	simvastatin  	 JJ	I-NP
daily 	daily 	 JJ	I-NP
.  	.  	 .	O
The  	The  	 DT	O
primary  	primary  	 JJ	B-NP
composite  	composite  	 JJ	I-NP
endpoint  	endpoint  	 NN	I-NP
is  	is  	 VBZ	O
the  	the  	 DT	O
occurrence  	occurrence  	 NN	O
of  	of  	 IN	O
cardiovascular  	cardiovascular  	 JJ	B-NP
death 	death 	 NN	I-NP
,  	,  	 ,	O
non-fatal  	non-fatal  	 JJ	B-NP
myocardial  	myocardial  	 JJ	I-NP
infarction 	infarction 	 NN	I-NP
,  	,  	 ,	O
or  	or  	 CC	O
rehospitalization  	rehospitalization  	 NN	B-NP
for  	for  	 IN	O
an  	an  	 DT	O
acute  	acute  	 JJ	B-NP
coronary  	coronary  	 JJ	I-NP
syndrome  	syndrome  	 NN	I-NP
( 	( 	 -LRB-	O
ACS 	ACS 	 NNP	B-NP
)  	)  	 -RRB-	O
at  	at  	 IN	O
one  	one  	 CD	O
year 	year 	 NN	O
.  	.  	 .	O
If  	If  	 IN	O
A-2-Z  	A-2-Z  	 NNP	B-NP
demonstrates  	demonstrates  	 VBZ	O
significant  	significant  	 JJ	O
reductions  	reductions  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
adverse  	adverse  	 JJ	O
events  	events  	 NNS	O
during  	during  	 IN	O
the  	the  	 DT	O
first  	first  	 JJ	O
four  	four  	 CD	O
months 	months 	 NNS	O
,  	,  	 ,	O
it  	it  	 PRP	O
would  	would  	 MD	O
suggest  	suggest  	 VB	O
an  	an  	 DT	O
incremental  	incremental  	 JJ	B-NP
clinical  	clinical  	 JJ	I-NP
benefit  	benefit  	 NN	I-NP
from  	from  	 IN	O
initiating  	initiating  	 VBG	O
these  	these  	 DT	O
agents  	agents  	 NNS	O
early  	early  	 RB	O
after  	after  	 IN	O
an  	an  	 DT	O
acute  	acute  	 JJ	B-NP
coronary  	coronary  	 JJ	I-NP
syndrome 	syndrome 	 NN	I-NP
.  	.  	 .	O
If  	If  	 IN	O
benefits  	benefits  	 NNS	O
accrue 	accrue 	 NN	B-NP
,  	,  	 ,	O
but  	but  	 CC	O
do  	do  	 VBP	O
so  	so  	 RB	O
later  	later  	 RB	O
during  	during  	 IN	O
follow  	follow  	 VB	O
up 	up 	 RP	O
,  	,  	 ,	O
it  	it  	 PRP	O
would  	would  	 MD	O
be  	be  	 VB	O
difficult  	difficult  	 JJ	O
to  	to  	 TO	O
discriminate  	discriminate  	 VB	O
between  	between  	 IN	O
the  	the  	 DT	O
effects  	effects  	 NNS	O
of  	of  	 IN	O
more  	more  	 RBR	O
aggressive  	aggressive  	 JJ	O
vs.  	vs.  	 NN	O
earlier  	earlier  	 RBR	O
lipid  	lipid  	 JJ	B-NP
lowering  	lowering  	 JJ	I-NP
therapy 	therapy 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
Pravastatin  	Pravastatin  	 NNP	B-NP
or  	or  	 CC	O
Atorvastatin  	Atorvastatin  	 NNP	B-NP
Evaluation  	Evaluation  	 NNP	I-NP
and  	and  	 CC	O
Infection  	Infection  	 NNP	B-NP
Therapy  	Therapy  	 NNP	I-NP
( 	( 	 -LRB-	O
PROVE  	PROVE  	 NNP	O
IT 	IT 	 NNP	O
)  	)  	 -RRB-	O
trial  	trial  	 NN	O
is  	is  	 VBZ	O
looking  	looking  	 VBG	O
at  	at  	 IN	O
4,000  	4,000  	 CD	O
patients  	patients  	 NNS	O
within  	within  	 IN	O
10  	10  	 CD	O
days  	days  	 NNS	O
of  	of  	 IN	O
an  	an  	 DT	O
acute  	acute  	 JJ	B-NP
coronary  	coronary  	 JJ	I-NP
syndrome  	syndrome  	 NN	I-NP
and  	and  	 CC	O
randomizing  	randomizing  	 VBD	O
them  	them  	 PRP	O
to  	to  	 TO	O
either  	either  	 DT	O
pravastatin  	pravastatin  	 JJ	O
40  	40  	 CD	O
mg  	mg  	 NNS	B-NP
or  	or  	 CC	O
atorvastatin  	atorvastatin  	 CD	B-NP
80  	80  	 CD	O
mg  	mg  	 CD	B-NP
daily  	daily  	 JJ	O
[  	[  	 -LRB-	O
29  	29  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
Patients  	Patients  	 NNS	O
will  	will  	 MD	O
be  	be  	 VB	O
observed  	observed  	 VBN	O
over  	over  	 RP	O
at  	at  	 IN	O
least  	least  	 JJS	O
1.5  	1.5  	 CD	O
years  	years  	 NNS	O
for  	for  	 IN	O
the  	the  	 DT	O
occurrence  	occurrence  	 NN	O
of  	of  	 IN	O
myocardial  	myocardial  	 JJ	B-NP
infarction  	infarction  	 NN	I-NP
or  	or  	 CC	O
other  	other  	 JJ	O
cardiovascular  	cardiovascular  	 JJ	B-NP
events 	events 	 NNS	I-NP
.  	.  	 .	O
Unlike 	Unlike 	 NNP	O
,  	,  	 ,	O
MIRACL  	MIRACL  	 NNP	B-NP
and  	and  	 CC	O
the  	the  	 DT	O
A-2-Z  	A-2-Z  	 CD	B-NP
trials 	trials 	 NNS	I-NP
,  	,  	 ,	O
this  	this  	 DT	O
study  	study  	 NN	O
will  	will  	 MD	O
not  	not  	 RB	O
assess  	assess  	 VB	O
the  	the  	 DT	O
efficacy  	efficacy  	 NN	O
of  	of  	 IN	O
early  	early  	 JJ	O
statin  	statin  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
after  	after  	 IN	O
an  	an  	 DT	O
acute  	acute  	 JJ	B-NP
coronary  	coronary  	 JJ	I-NP
syndrome 	syndrome 	 NN	I-NP
;  	;  	 :	O
rather 	rather 	 RB	O
,  	,  	 ,	O
it  	it  	 PRP	O
will  	will  	 MD	O
examine  	examine  	 VB	O
the  	the  	 DT	O
role  	role  	 NN	O
of  	of  	 IN	O
more  	more  	 JJR	O
vs.  	vs.  	 IN	O
less  	less  	 RBR	O
aggressive  	aggressive  	 JJ	O
lipid-lowering  	lipid-lowering  	 NN	O
in  	in  	 IN	O
this  	this  	 DT	O
setting 	setting 	 NN	O
.  	.  	 .	O
In  	In  	 IN	O
2002 	2002 	 CD	O
,  	,  	 ,	O
many  	many  	 JJ	O
would  	would  	 MD	O
consider  	consider  	 VB	O
it  	it  	 PRP	O
unethical  	unethical  	 VBP	O
to  	to  	 TO	O
withhold  	withhold  	 VB	O
statins  	statins  	 VBN	O
from  	from  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
established  	established  	 JJ	O
coronary  	coronary  	 JJ	B-NP
disease 	disease 	 NN	I-NP
.  	.  	 .	O
This  	This  	 DT	O
makes  	makes  	 VBZ	O
it  	it  	 PRP	O
unlikely  	unlikely  	 RB	O
that  	that  	 IN	O
additional  	additional  	 JJ	O
placebo-controlled  	placebo-controlled  	 JJ	O
trials  	trials  	 NNS	O
will  	will  	 MD	O
be  	be  	 VB	O
carried  	carried  	 VBN	O
out  	out  	 RP	O
in  	in  	 IN	O
this  	this  	 DT	O
area 	area 	 NN	O
.  	.  	 .	O
Future  	Future  	 JJ	B-NP
secondary  	secondary  	 JJ	I-NP
prevention  	prevention  	 NN	I-NP
studies  	studies  	 NNS	I-NP
should  	should  	 MD	O
look  	look  	 VB	O
at  	at  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
stable  	stable  	 JJ	O
or  	or  	 CC	O
unstable  	unstable  	 JJ	O
disease  	disease  	 NN	O
and  	and  	 CC	O
will  	will  	 MD	O
need  	need  	 VB	O
to  	to  	 TO	O
address  	address  	 VB	O
the  	the  	 DT	O
comparative  	comparative  	 JJ	B-NP
efficacy  	efficacy  	 NN	I-NP
of  	of  	 IN	O
different  	different  	 JJ	O
statins  	statins  	 NNS	B-NP
( 	( 	 -LRB-	O
or  	or  	 CC	O
newer  	newer  	 JJR	O
agents 	agents 	 NNS	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
assess  	assess  	 VB	O
the  	the  	 DT	O
incremental  	incremental  	 JJ	B-NP
benefit  	benefit  	 NN	I-NP
of  	of  	 IN	I-NP
combination  	combination  	 NN	I-NP
therapy  	therapy  	 NN	I-NP
[  	[  	 -LRB-	O
30  	30  	 CD	O
]  	]  	 -RRB-	O
and  	and  	 CC	O
determine  	determine  	 VB	O
whether  	whether  	 IN	O
there  	there  	 EX	O
is  	is  	 VBZ	O
a  	a  	 DT	O
serum  	serum  	 JJ	B-NP
cholesterol  	cholesterol  	 NN	I-NP
' 	' 	 POS	O
floor 	floor 	 NN	O
'  	'  	 ''	O
below  	below  	 IN	O
which  	which  	 WDT	O
reductions  	reductions  	 NNS	O
are  	are  	 VBP	O
unlikely  	unlikely  	 JJ	O
to  	to  	 TO	O
provide  	provide  	 VB	O
further  	further  	 RBR	O
clinical  	clinical  	 JJ	B-NP
benefit 	benefit 	 NN	I-NP
.  	.  	 .	O
Competing  	Competing  	 VBG	B-NP
interests  	interests  	 NNS	I-NP
Dr  	Dr  	 NNP	O
Aronow  	Aronow  	 NNP	O
has  	has  	 VBZ	O
received  	received  	 VBN	O
honoraria  	honoraria  	 VBN	O
as  	as  	 IN	O
a  	a  	 DT	O
speaker  	speaker  	 NN	O
and  	and  	 CC	O
advisory  	advisory  	 JJ	B-NP
board  	board  	 NN	I-NP
member  	member  	 NN	I-NP
for  	for  	 IN	I-NP
Pfizer  	Pfizer  	 NNP	I-NP
and  	and  	 CC	O
as  	as  	 IN	O
a  	a  	 DT	O
speaker  	speaker  	 NN	O
for  	for  	 IN	O
Merck 	Merck 	 NNP	O
.  	.  	 .	O
Abbreviations  	Abbreviations  	 NNP	B-NP
HMG  	HMG  	 NNP	I-NP
CoA  	CoA  	 NNP	I-NP
=  	=  	 SYM	O
3-Hydroxy-3-methylgluatryl  	3-Hydroxy-3-methylgluatryl  	 FW	O
coenzyme  	coenzyme  	 FW	O
A 	A 	 NNP	O
;  	;  	 :	O
MIRACL  	MIRACL  	 NNP	B-NP
=  	=  	 NNP	O
Myocardial  	Myocardial  	 NNP	B-NP
Ischemia  	Ischemia  	 NNP	I-NP
Reduction  	Reduction  	 NNP	I-NP
with  	with  	 IN	O
Aggressive  	Aggressive  	 NNP	B-NP
Cholesterol  	Cholesterol  	 NNP	I-NP
Lowering 	Lowering 	 NNP	O
;  	;  	 :	O
LDL  	LDL  	 NNP	B-NP
=  	=  	 SYM	O
low  	low  	 JJ	O
density  	density  	 NN	B-NP
lipoprotein 	lipoprotein 	 NNS	I-NP
;  	;  	 :	O
RR  	RR  	 NNP	B-NP
=  	=  	 SYM	O
relative  	relative  	 JJ	B-NP
risk 	risk 	 NN	I-NP
;  	;  	 :	O
CI  	CI  	 NNP	O
=  	=  	 SYM	O
confidence  	confidence  	 NN	B-NP
interval 	interval 	 NNS	I-NP
;  	;  	 :	O
HDL  	HDL  	 NNP	B-NP
=  	=  	 SYM	O
high  	high  	 JJ	O
density  	density  	 NN	B-NP
lipoprotein 	lipoprotein 	 NNS	I-NP
;  	;  	 :	O
PTCA  	PTCA  	 NNP	B-NP
=  	=  	 SYM	O
percutaneous  	percutaneous  	 FW	B-NP
transluminal  	transluminal  	 FW	I-NP
coronary  	coronary  	 FW	I-NP
angioplasty 	angioplasty 	 FW	I-NP
;  	;  	 :	O
CABG  	CABG  	 NNP	B-NP
=  	=  	 SYM	O
coronary  	coronary  	 FW	B-NP
artery  	artery  	 FW	I-NP
bypass  	bypass  	 FW	I-NP
graft 	graft 	 FW	I-NP
;  	;  	 :	O
ECG  	ECG  	 NNP	B-NP
=  	=  	 SYM	O
electrocardiogram 	electrocardiogram 	 FW	O
;  	;  	 :	O
A-2-Z  	A-2-Z  	 CD	B-NP
=  	=  	 SYM	O
Aggrastat  	Aggrastat  	 NNP	B-NP
to  	to  	 TO	O
Zocor 	Zocor 	 NNP	B-NP
;  	;  	 :	O
ACS  	ACS  	 NNP	B-NP
=  	=  	 SYM	O
acute  	acute  	 FW	B-NP
coronary  	coronary  	 FW	I-NP
syndrome 	syndrome 	 FW	I-NP
;  	;  	 :	O
PROVE  	PROVE  	 NNP	O
IT  	IT  	 NNP	O
=  	=  	 NNP	O
Pravastatin  	Pravastatin  	 NNP	B-NP
or  	or  	 CC	O
Atorvastatin  	Atorvastatin  	 NNP	B-NP
Evaluation  	Evaluation  	 NNP	I-NP
and  	and  	 CC	O
Infection  	Infection  	 NNP	B-NP
Therapy 	Therapy 	 NNP	I-NP
.  	.  	 .	O
